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Abstract Compressive osseointegration technology,
which provides immediate, mechanically compliant endo-
prosthetic ﬁxation, has been adapted for massive proximal
tibial reconstructions in an attempt to avoid aseptic failure
encountered with conventional stems. A retrospective
review of 16 patients with resected tumors was undertaken
to determine whether compressive osseointegration can
provide durable anchorage of tibial implants. Medical
records, radiographs, and clinical examinations were
reviewed to assess surgical, local disease control, and
prosthetic outcomes. The average age was 18 years (range,
12–42 years). Diagnoses included osteosarcoma (12),
Ewing sarcoma (two), chondrosarcoma (one), and undif-
ferentiated sarcoma (one). Minimum followup was 2 years
(mean, 4.5 years; range, 2–10.3 years); no patient was lost
to followup. There were no local recurrences. Four patients
developed metastatic disease; one patient died of his pri-
mary tumor, and another died from a chemotherapy-related
malignancy. Complications included one early deep
infection that ultimately resulted in prosthetic loosening
and the need for an above-knee amputation. There were
two late deep infections; prosthetic retention was achieved
with de ´bridement and antibiotics. One patient developed
aseptic loosening and underwent revision; the other 15
implants provided stable osseointegration at last followup.
Compressive osseointegration technology can thus achieve
acceptable short-term endoprosthetic ﬁxation results and
may reduce the risk of aseptic loosening reported with
conventional tibial stems.
Level of Evidence: Level IV, therapeutic study. See
Guidelines for Authors for a complete description of levels
of evidence.
Introduction
A good deal has been reported about the outcomes of
massive distal femoral endoprosthetic reconstructions after
tumor resection. Recent studies have described distal
femoral endoprosthetic survivorship at 10 years to range
upward of 80% [6, 31, 39]. Less is known about proximal
tibial oncologic reconstructive outcomes for a number of
reasons. First, although the incidence of proximal tibial
tumors ranks next to distal femoral lesions, the latter
remain roughly twice as common [48]. Second, amputation
is more often necessary for proximal tibial neoplasms
because of neurovascular involvement. Third, the com-
paratively greater challenges posed by the reestablishment
of extensor mechanism function after proximal tibial
resection have led to the use of a variety of tibial recon-
structive methods, including arthrodesis [12], allografts
[10, 14, 43], and alloprostheses [5, 17, 51] with relatively
fewer endoprosthetic reconstructions. Furthermore,
although intermediate-term (ie, 5–10 years) prosthetic
survivorship of a variety of distal femoral implants is
reasonably predictable and acceptable [6, 33, 41, 45], tibial
endoprosthetic reconstruction is more challenging
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on tibial stems. Two- to 5-year failure rates resulting from
aseptic loosening have ranged from 3% to 46% in a variety
of series [19, 22, 24, 26, 29, 34, 35].
Compressive osseointegration technology was devel-
oped in an attempt to provide secure, long-term anchorage
of oncologic endoprostheses by using a spring-loaded
device to achieve compliant prestress ﬁxation, thus
avoiding complications of stress shielding and particle-
induced osteolysis [8, 15, 27, 36]. Initial distal femoral
radiographic results have conﬁrmed progressive bone
hypertrophy at the prosthetic interface [3] and early clinical
comparisons with cemented stems [4] have demonstrated
equivalent prosthetic survivorship at 2 years.
For primary tumor proximal tibial resections managed
with compressive osseointegration reconstructions, the
purposes of this study were to determine (1) the rates of
local control and prosthetic survival; (2) the frequency and
nature of surgical complications; (3) and the outcome of
prosthetic revision.
Materials and Methods
I retrospectively reviewed 16 patients with resected
malignancies reconstructed with a proximal tibial Com-
press1 device (Biomet, Inc, Warsaw, IN) between April
1998 and September 2006. There were seven males and
nine females with an average age of 18 years (range, 12–
42 years). Diagnoses included osteosarcoma (12), Ewing’s
sarcoma (two), chondrosarcoma (one), and undifferentiated
sarcoma (one). Distal femoral Compress1 devices, ini-
tially introduced in 1993, were granted US Food and Drug
Administration clearance in December 2003. On a custom
off-label basis, Compress1 implants have been available
for proximal tibial reconstructions since 1998. The mini-
mum followup was 2 years (mean, 4.5 years; range,
2–10.3 years). No patient was lost to followup. Prior
Institutional Review Board approval was obtained for this
retrospective review.
Previously published methods of proximal tibial resec-
tion and endoprosthetic reconstruction were followed
[7, 13, 16, 18, 23, 28, 30, 36, 50]. A sufﬁcient amount of
proximal tibia was removed to achieve negative surgical
margins. Resection length averaged 17 cm (range, 13–
24 cm); remaining distal tibial segments averaged 20 cm
(range, 11–25 cm); percentage of tibia resected averaged
46% (range, 35%–65%). The tibial canal was reamed to
allow placement of a 10-mm anchor plug and a centering
sleeve of at least 12 mm diameter. Compression force (in
pounds) was as follows: 400 (ﬁve), 600 (10), and 800
(one); two short custom spindles were used. Over time, we
have empirically preferred 600-pound small, short
hydroxyapatite spindles for tibial reconstructions. Twelve
patients underwent extensor mechanism reinforcement and
soft tissue coverage with a gastrocnemius ﬂap.
Continuous passive motion of the knee was begun 48
hours after surgery or as soon as permitted by the plastic
surgery staff. Quadriceps sets and straight leg raising
exercises were begun 2 weeks after surgery, but progres-
sive resistive exercises were not undertaken. In contrast to
rehabilitation of patients with cemented stems, for which
full weight can be borne immediately, weightbearing on
the tibial Compress1 implant was withheld for 3 months
postoperatively, after which time weightbearing was
advanced at a rate of 25% of body weight per week.
Followup visits for routine clinical and radiographic
examinations generally occurred at 2, 6, and 12 weeks and
at 3-month intervals thereafter. Medical records were
reviewed to obtain demographic data, including age, gen-
der, diagnosis, and treatment information. Operative
reports were studied to record technical factors, including
implant length relative to remaining distal tibial length,
compression force, and spindle length. Major complica-
tions such as aseptic loosening, infection, local recurrence,
periprosthetic fracture, need for further surgery, metastatic
disease, and death were recorded. Device-related mechan-
ical failure was deﬁned as the need for revision secondary
to aseptic loosening.
I assessed postoperative radiographs at 3- to 6-month
intervals for indications of technical error (pin malposition
or migration) and for evidence of device-related failure
(lucency at the bone-prosthetic interface, endosteal erosion,
loss of compression distance, gross loosening, and implant
breakage).
Results
There were no local recurrences. Four patients had meta-
static disease at last followup. Two deaths occurred; one
patient died secondary to osteosarcoma, and one developed
myeloﬁbrosis.
Surgical complications included one early deep infection
that ultimately resulted in prosthetic loosening and the need
for an above-knee amputation. There were two late deep
prosthetic infections; prosthetic retention was achieved with
de ´bridement and antibiotics. There were two nondisplaced
tibial fractures, not associated with the hardware, which
were treated nonoperatively. There were no prosthetic
fractures or other forms of mechanical breakage. All
patients were able to walk without an assistive device.
There was one device-related aseptic mechanical failure
of the Compress1 device (Fig. 1). At 3.2 years after the
index procedure, revision to a slightly longer Compress1
tibial replacement was successfully accomplished. All
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123other implants demonstrated radiographic signs of stable
osseointegration as evidenced by bone hypertrophy at the
prosthetic interface and lack of stress shielding (Fig. 2).
Design modiﬁcations over the study period, in terms of
compression force or spindle type, did not correlate with
any observable changes in the degree of osseointegration.
Discussion
The rationale of this study was to better understand the
short-term outcomes of compressive osseointegration
technology when used for reconstruction of massive
defects after primary oncologic resection. The primary
aims were the determination of prosthetic survival and
management of revisions. The secondary aims were doc-
umentation of local control and surgical complications.
Limitations of this study include the small number of
patients, the lack of control subjects, and the limited fol-
lowup. The limited study size makes statistical analysis
difﬁcult, especially in terms of meaningful calculation of
implant survival analysis. With average 4.5-year followup,
the data in this study should be viewed as preliminary with
results needing to be further developed to substantiate
conclusions regarding prosthetic longevity. However,
given the relative infrequency of primary oncologic prox-
imal tibial reconstructions, this review of 16 patients is one
of the larger series of uncemented devices and the only one
that relates to compressive osseointegration technology.
Except for the two patients who died, all of the patients
reported continue to be examined regularly so the longer-
term durability of the implant can be determined.
Effective reconstruction of massive defects after resec-
tion of proximal tibial neoplasms is challenging for several
reasons. First, as compared with femoral presentations, the
size of tibial tumors and the close proximity of surrounding
neurovascular structures often render decision-making
regarding limb salvage difﬁcult. As compared with distal
femoral tumors, achieving local control of tibial lesions
more often necessitates amputation. The correspondingly
fewer patients who do receive prosthetic reconstructions
may still be at high risk for local recurrence. Although not
directly a product of osseointegration technology, the
ﬁnding that all patients in this study demonstrated local
control is nonetheless reassuring in terms of validating a
limb salvage approach in a carefully selected population.
A second difﬁculty of tibial prosthetic reconstruction is
the considerable biomechanical stress placed on conven-
tional tibial intramedullary stems, which has been
associated with relatively high rates of mechanical failure
resulting from prosthetic fracture and aseptic loosening.
Determination of the inﬂuence of mechanical failure on
rates of proximal tibial prosthetic survivorship, based on
the extant literature, is difﬁcult. Many studies combine
outcomes of proximal tibial implants with those from other
anatomic locations, including the distal and proximal
Fig. 1A–B Anteroposterior (A) and lateral (B) radiographs of failed
Compress1 proximal tibial replacement demonstrates radiolucencies
at the bone-prosthetic interface and loss of compression distance.
Fig. 2A–B Anteroposterior (A) and lateral (B) radiographic images
demonstrate stable osseointegration of a Compress1 proximal tibial
replacement at 9.3 years postimplantation.
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123femur [2, 5, 9, 20, 21, 26, 29, 31, 32, 38–40, 42, 44, 47, 49,
51]. When reported separately, proximal tibial results fre-
quently detail all-cause failure combining the effects of
infection, local recurrence, fracture, and other mechanical
issues on prosthetic retention [26, 29, 31, 32, 47]. Some
papers have few patients and/or short followup [1, 2, 9, 37,
52, 53], whereas some that describe experience extending
over several decades combine the ﬁndings with several
distinct proximal tibial implant designs and surgical tech-
niques [5, 26, 29, 32, 39, 42, 47]. To the extent that rates of
proximal tibial endoprosthetic mechanical failure can be
determined from the literature over the past 20 years, most
authors report ﬁgures of 10% to 30% failure at 5- to 10-
year followup (Table 1). The most promising long-term
results were reported by Myers et al, who described a 9%
rate of aseptic loosening in 99 rotating hinge devices at
15 years of followup, although seven prosthetic fractures
should be added to estimate the actual mechanical failure
rate [34]. Subsequently, this group reported longer expe-
rience with a variety of proximal tibial implants, for which
mechanical failure rates of 37.5% and 59.4% were reported
at 10 and 20 years, respectively [25]. The addition of
porous- or hydroxyapatite-coated collars at the bone-pros-
thetic interface seems to hold the promise of improving
longevity of conventional cemented or uncemented stems
[9, 34, 46]. This study of primary oncologic reconstructions
was undertaken to speciﬁcally determine the intermediate-
term mechanical failure rate of a single type of proximal
tibial endoprosthesis that uses a novel means of achieving
compressive osseointegration. At an average of 4.5 years
followup, only one prosthetic failure resulting from
mechanical loosening of the implant was noted. This result
compares favorably with other types of proximal tibial
implants reported in the literature. The Compress1 device
would thus seem to provide an effective means of pro-
viding stable ﬁxation for massive proximal tibial
reconstructions after primary oncologic resection. Initial
results suggest Compress1 technology may well serve to
avoid the problems of prosthetic breakage, stress shielding,
and particle-induced osteolytic loosening that are associ-
ated with conventional tibial stems.
A third problematic aspect of tibial reconstruction
involves soft tissue coverage and the consequent risk of
prosthetic infection. One patient without ﬂap coverage in
this series developed an infection that ultimately necessi-
tated an amputation; the two other patients who developed
a deep infection retained their implants, perhaps in part
because they had received a ﬂap as part of their index
procedure. The utility of the gastrocnemius ﬂap in
decreasing the risk of tibial prosthetic infection and in
improving extensor mechanism reconstitution serves to
makes its use routine [7, 11].
A ﬁnal challenge of tibial reconstruction is the frequent
need to salvage short metadiaphyseal fragments remaining
Table 1. Proximal tibial endoprosthetic mechanical failure rate at intermediate followup
Study Year Device description Patients
(number)
Average
followup (years)
Mechanical
failure rate
Comment
Jeys et al. [25] 2008 Cemented custom constrained
and rotating hinge
136 10 31.4 Mechanical failure rate (31.4%)
Myers et al. [34] 2007 Cemented custom constrained
hinge
95 5 16 Aseptic loosening (16%) plus ﬁve
prosthetic fractures
Myers et al. [34] 2007 Cemented custom rotating hinge,
hydroxyapatite collar
99 5 3 Aseptic loosening (3%) plus seven
prosthetic fractures
Flint et al. [19] 2006 Uncemented modular
constrained hinge
44 3 6.8 Stem breakage (two); rotational
instability (one)
Gosheger et al. [20] 2006 Uncemented modular
rotating hinge
42 4 9.5 Aseptic loosening (three); stem
breakage (one)
Ahlmann et al. [2] 2006 Cemented modular
rotating hinge
30 3 10 Fatigue fracture (two); aseptic
loosening (one)
Torbert et al. [44] 2005 Cemented modular
rotating hinge
26 5 19.2 Mechanical failure (three); aseptic
loosening (one); dislocation (one)
Natarajan et al. [35] 2003 Cemented custom constrained
and rotating hinge
133 5 10.5 Fracture revision (seven); aseptic
loosening (ﬁve); disassembly
(one); bending (one)
Kawai et al. [26] 1999 Uncemented (ﬁve) and
cemented (two) rotating hinge
7 2 to 7 28.6 Tibial yoke breakage (two)
Horowitz et al. [24] 1991 Cemented custom constrained
hinge
16 5 25 Aseptic loosening (three);
articulation fracture (one)
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123after tumor resection or revision. The ‘‘bone-sparing’’
nature of the Compress1 device (as little as 43 mm of
bone can be implanted) and the relative ease of revision
after infection, fracture, or mechanical loosening (the
device is readily removed and as little as 1 cm of additional
bone needs to be resected at the time of reimplantation) are
highlighted by the successful revision of the sole case of
mechanical failure (Fig. 1)[ 36].
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